Safety issues with iron sucrose.

[1]  J. Yee,et al.  Iron sucrose: the oldest iron therapy becomes new. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  C. Chaimovitz,et al.  Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  G. London,et al.  Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease , 2002, Circulation.

[4]  R. Zager,et al.  Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  T. Rabelink,et al.  Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo , 2002, European journal of clinical investigation.

[6]  S. Kersting,et al.  Nontransferrin‐bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion , 2002, European journal of clinical investigation.

[7]  J. Parkkinen,et al.  Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  P. Geisser,et al.  Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. , 1996, Arzneimittel-Forschung.